Negative correlation of Nogo-A with the malignancy of oligodendroglial tumor

Nan-Xiang Xiong1, Hong-Yang Zhao, Fang-Cheng Zhang

  • 1Department of Neurosurgery, Xiehe Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.

Neuroscience Bulletin
|June 27, 2007
PubMed
Abstract

Insights

Nogo-A expression is linked to lower oligodendroglial tumor malignancy. Higher Nogo-A levels correlate with less aggressive tumors, suggesting a potential role in tumor suppression.

Area of Science:

  • Neuroscience
  • Oncology
  • Molecular Biology

Background:

  • Nogo-A is an inhibitor of axon regeneration in the central nervous system (CNS).
  • The specific role of Nogo-A in CNS tumors, particularly oligodendroglial tumors, remains largely uncharacterized.
  • Understanding Nogo-A's function could reveal new therapeutic targets for brain tumors.

Purpose of the Study:

  • To investigate the relationship between Nogo-A expression and the malignancy grade of oligodendroglial tumors.
  • To determine if Nogo-A levels correlate with specific morphological features indicative of tumor aggressiveness.

Main Methods:

  • Immunohistochemistry and Western blot analysis were used to detect Nogo-A expression in oligodendroglial tumor samples.
  • Tumor tissues, including oligodendroglioma and anaplastic oligodendroglioma, were analyzed.
  • Correlation tests were performed between Nogo-A expression and tumor morphological changes (atypical cell percentage, mitotic index).

Main Results:

  • A significant negative correlation was observed between Nogo-A expression and tumor tissue morphological changes.
  • Immunohistochemistry indicated lower Nogo-A expression in more malignant tumors.
  • Western blot analysis revealed significantly higher Nogo-A protein levels in oligodendroglioma compared to anaplastic oligodendroglioma.

Conclusions:

  • Nogo-A expression is negatively correlated with the malignancy grade of oligodendroglial tumors.
  • Reduced Nogo-A expression is associated with increased tumor aggressiveness.
  • These findings suggest Nogo-A may play a role in suppressing oligodendroglial tumor progression.

Related Concept Videos

Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Notch Signaling Pathway03:14

Notch Signaling Pathway

The Notch signaling pathway is a major intracellular signaling pathway that is highly conserved over a broad spectrum of metazoan species. It stands unique from other intracellular signaling mechanisms in animals because notch protein itself acts as the receptor as well as the primary signaling molecule.
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not until 1985...